The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.
Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes
Open accessAbstract
Given its critical role in T-cell signaling, interleukin-2-inducible kinase (ITK) is an appealing therapeutic target that can contribute to the pathogenesis of certain infectious, autoimmune, and neoplastic diseases. Ablation of ITK subverts Th2 immunity, thereby potentiating Th1-based immune responses. While small-molecule ITK inhibitors have been identified, none have demonstrated clinical utility. Ibrutinib is a confirmed irreversible inhibitor of Bruton tyrosine kinase (BTK) with outstanding clinical activity and tolerability in B-cell malignancies. Significant homology between BTK and ITK alongside in silico docking studies support ibrutinib as an immunomodulatory inhibitor of both ITK and BTK. Our comprehensive molecular and phenotypic analysis confirms ITK as an irreversible T-cell target of ibrutinib. Using ibrutinib clinical trial samples along with well-characterized neoplastic (chronic lymphocytic leukemia), parasitic infection (Leishmania major), and infectious disease (Listeria monocytogenes) models, we establish ibrutinib as a clinically relevant and physiologically potent ITK inhibitor with broad therapeutic utility. This trial was registered at www.clinicaltrials.gov as #NCT01105247 and #NCT01217749.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although ibrutinib inhibits other similar kinases that contain C481, including ITK and BLK,7,22”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“At relapse, none of the patients had mutations in other kinases containing a cysteine residue homologous to C481 in BTK that are irreversibly inhibited by ibrutinib”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“mutations have not been observed in these other targets, findings that suggest that BTK is its critical target.”
From Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib (2014) · cites this paper as [22]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004594107 · Cited by 1,561
Self-citationAdvani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128 · cited 1×
“Irreversible ITK binding, ITK signal inhibition, and Th1-skewed cytokine patterns were also identified in CLL patients treated with ibrutinib in 2 clinical trials.(37,38) These findings were validated using a well-established mouse model of cutaneous leishmaniasis, and further clinical relevance was demonstrated using…”
BackgroundSelf-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citationLong-term Outcome of 525 Patients With Mycosis Fungoides and Sézary Syndrome
Kim, Y. H., Liu, H. L., Mraz‐Gernhard, S., Varghese, A., & Hoppe, R. T. (2003) · Archives of Dermatology · doi:10.1001/archderm.139.7.857 · Cited by 652
Ramsay, A. G., Johnson, A. J., Lee, A. M., Görgün, G., Dieu, R. L., Blum, W. G., Byrd, J. C., & Gribben, J. G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35017 · Cited by 619
Self-citationMarks, D. I., Paietta, E. M., Moorman, A. V., Richards, S. M., Buck, G. A. N., Dewald, G. W., Ferrando, A. A., Fielding, A. K., Goldstone, A. H., Ketterling, R. P., et al. (2009) · Blood · doi:10.1182/blood-2009-08-231217 · Cited by 420
The B-cell receptor signaling pathway as a therapeutic target in CLL
Woyach, J. A., Johnson, A. J., & Byrd, J. C. (2012) · Blood · doi:10.1182/blood-2012-02-362624 · Cited by 412
Self-citationRequirement for Tec Kinases Rlk and Itk in T Cell Receptor Signaling and Immunity
Schaeffer, E. M., Debnath, J., Yap, G. S., McVicar, D. W., Liao, X. C., Littman, D. R., Sher, A., VARMUS, H. E., Lenardo, M. J., & Schwartzberg, P. L. (1999) · Science · doi:10.1126/science.284.5414.638 · Cited by 398
TEC FAMILY KINASES IN T LYMPHOCYTE DEVELOPMENT AND FUNCTION
Berg, L. J., Finkelstein, L. D., Lucas, J. A., & Schwartzberg, P. L. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104743 · Cited by 341
Liu, K., Bunnell, S. C., Gurniak, C. B., & Berg, L. J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.10.1721 · Cited by 337
Cited by
Sorted by citations
Items 401–500 of 813
Ibrutinib-related uveitis: A case series
Chiu, Z. K., Goh, J., Ling, C., Lin, M., & Hall, A. J. H. (2022) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2022.101300 · Cited by 18
Emerging Therapies for the Management of Richter Transformation
Smyth, E., Eyre, T. A., & Cheah, C. Y. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01028 · Cited by 18
Pyrazolopyridine-based kinase inhibitors for anti-cancer targeted therapy
Halder, P., Rai, A., Talukdar, V., Das, P., & Lakkaniga, N. R. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00003j · Cited by 18
Anti-leishmanial therapies: overcoming current challenges with emerging therapies
Sundar, S., Madhukar, P., & Kumar, R. (2024) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2024.2438627 · Cited by 18
Butler, L. A., Tam, C. S. L., & Seymour, J. F. (2017) · Blood Reviews · doi:10.1016/j.blre.2017.05.002 · Cited by 18
Ibrutinib Therapy and Mycobacterium chelonae Skin and Soft Tissue Infection
Dousa, K. M., Babiker, A., Aartsen, D. V., Shah, N. B., Bonomo, R. A., Johnson, J. L., & Skalweit, M. J. (2018) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofy168 · Cited by 18
Is ibrutinib associated with disseminated cryptococcosis with CNS involvement?
Abid, M. B., Stromich, J. J., & Gundacker, N. D. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1508622 · Cited by 18
The B‐cell receptor in control of tumor B‐cell fitness: Biology and clinical relevance
Casola, S. S., Perucho, L., Tripodo, C., Sindaco, P., Ponzoni, M., & Facchetti, F. (2019) · Immunological Reviews · doi:10.1111/imr.12738 · Cited by 18
Sharif-Askari, B., Doyon, D., Paliouras, M., & Aloyz, R. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-47305-2 · Cited by 18
Emerson, D. A., Rolig, A. S., & Redmond, W. L. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0338 · Cited by 18
TP53 dysfunction in CLL: Implications for prognosis and treatment
Raa, G. D. T., & Kater, A. P. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.08.002 · Cited by 18
Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia
Lewis, R. I., Stein, A. F. V., & Hallek, M. J. (2024) · Blood · doi:10.1182/blood.2023022861 · Cited by 17
Ondrišová, L., Šeda, V., Hlavac, K., Petra, P., Hoferkova, E., Chiodin, G., Košťálová, L., Pavlasová, G. M., Filip, D., Večeřa, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173770 · Cited by 17
Ibrutinib: a paradigm shift in management of CLL
Badar, T., Burger, J. A., Wierda, W. G., & O'Brien, S. M. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.977862 · Cited by 17
B-cell receptor pathway modulators in NHL
Blum, K. A. (2015) · Hematology · doi:10.1182/asheducation-2015.1.82 · Cited by 17
Gauthier, M., Durrieu, F., Martin, E., Pérès, M., Vergez, F., Filleron, T., Obéric, L., Bijou, F. D., Quillet‐Mary, A., & Ysebaert, L. (2019) · BMC Cancer · doi:10.1186/s12885-019-5971-z · Cited by 17
Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma
Makita, S., Hosoba, R., & Tobinai, K. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1802424 · Cited by 17
Cutaneous adverse‐events in patients treated with Ibrutinib
Pileri, A., Guglielmo, A., Agostinelli, C., Evangelista, V., Bertuzzi, C., Alessandrini, A. M., Bruni, F., Starace, M. V. R., Massi, A., Broccoli, A., et al. (2020) · Dermatologic Therapy · doi:10.1111/dth.14190 · Cited by 17
Yano, M., Byrd, J. C., & Muthusamy, N. (2022) · Cancers · doi:10.3390/cancers14235787 · Cited by 18
Self-citationNovel Therapies for Pemphigus Vulgaris
Altman, E. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00544-w · Cited by 17
Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation
Gu, Y., Huang, B., Yang, Y., Qi, M., Lu, G., Xia, D., & Li, H. (2018) · Inflammation · doi:10.1007/s10753-018-0745-3 · Cited by 17
The role of Th17 cells in chronic lymphocytic leukemia: friend or foe?
Gamal, W. M., Sahakian, E., & Pinilla-Ibarz, J. A. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008985 · Cited by 16
Hasan, M. N., Ray, M., & Saha, A. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.3c04710 · Cited by 16
IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma
Carson, C. C., Moschos, S. J., Edmiston, S. N., Darr, D. B., Nikolaishvili‐Feinberg, N., Groben, P. A., Zhou, X., Kuan, P. F., Pandey, S., Chan, K. T., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1826 · Cited by 16
Recent therapeutic advances in chronic lymphocytic leukemia
Bose, P., & Gandhi, V. V. (2017) · F1000Research · doi:10.12688/f1000research.11618.1 · Cited by 16
Stuehlinger, M., Weltermann, A., Staber, P. B., Heintel, D., Nösslinger, T., & Steurer, M. (2019) · Wiener klinische Wochenschrift · doi:10.1007/s00508-019-1534-1 · Cited by 16
Impact of COVID-19 in patients with lymphoid malignancies
Riches, J. C. (2021) · World Journal of Virology · doi:10.5501/wjv.v10.i3.97 · Cited by 16
Brown, L. C., Zhu, J., Desai, K. B., Kinsey, E. N., Kao, C., Lee, Y. H., Pabla, S., Labriola, M., Tran, J., Dragnev, K. H., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005249 · Cited by 16
Salhotra, A., Sandhu, K., O’Hearn, J., Ali, H., Nakamura, R., & Modi, B. G. (2022) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2023.2152330 · Cited by 16
Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia
Rey-Barroso, J., Munaretto, A., Rouquié, N., Mougel, A., Chassan, M., Gadat, S., Dewingle, O., Poincloux, R., Cadot, S., Ysebaert, L., et al. (2023) · Haematologica · doi:10.3324/haematol.2022.282466 · Cited by 16
The biology behind PI3K inhibition in chronic lymphocytic leukaemia
Ortiz‐Maldonado, V., García-Morillo, M., & Delgado, J. (2014) · Therapeutic Advances in Hematology · doi:10.1177/2040620714561581 · Cited by 16
Monocyte-to-macrophage switch reversibly impaired by Ibrutinib
Ferrarini, I., Rigo, A., Montresor, A., Laudanna, C., & Vinante, F. (2019) · Oncotarget · doi:10.18632/oncotarget.26744 · Cited by 16
Cardiovascular adverse events of ibrutinib
Ahn, I. E. (2019) · Blood · doi:10.1182/blood.2019002805 · Cited by 16
Ibrutinib-related uveitis: A report of two severe cases
Bohn, M., Bravo-Ljubetic, L., Lee, R., & Petrushkin, H. (2021) · European Journal of Ophthalmology · doi:10.1177/11206721211001268 · Cited by 15
Bruton’s tyrosine kinase regulates gut immune homeostasis through attenuating Th1 response
Guan, D., Wang, Z., Huo, J., Xu, S., & Lam, K. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03702-y · Cited by 15
Nikitin, E. A., Kislova, M. I., Morozov, D., Belyakova, V., Suvorova, A., Sveshnikova, J., Vyscub, G., Matveeva, I., Shirokova, M., Шипаева, А. Л., et al. (2023) · Leukemia · doi:10.1038/s41375-023-01891-3 · Cited by 15
Fu, Z., Huang, Z., Xu, H., Liu, Q., Li, J., Song, K., Deng, Y., Tao, Y., Zhang, H., Wang, P., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci178558 · Cited by 18
Mato, A. R., Jauhari, S., & Schuster, S. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24021 · Cited by 15
van Gelder, M., van Oers, M. H. J., Alemayehu, W. G., Abrahamse-Testroote, M. C. J., Cornelissen, J. J., Chamuleau, M. E. D., Zachée, P., Hoogendoorn, M., Nijland, M., Petersen, E. J., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.9 · Cited by 15
T‐Cell Immunopeptidomes Reveal Cell Subtype Surface Markers Derived From Intracellular Proteins
Olsson, N., Schultz, L. M., Zhang, L., Khodadoust, M. S., Narayan, R., Czerwinski, D. K., Levy, R., & Elias, J. E. (2018) · PROTEOMICS · doi:10.1002/pmic.201700410 · Cited by 15
Rodgers, T. D., & Reagan, P. M. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1479396 · Cited by 16
Proteolysis-targeting Chimeras for Targeting Protein for Degradation
Qi, J., & Zhang, G. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2018-0557 · Cited by 15
Bernard, R. S., & Hsia, C. C. (2015) · Annals of Hematology · doi:10.1007/s00277-015-2487-8 · Cited by 15
Roessner, P. M., Hanna, B. S., Öztürk, S., Schulz, R., Cid, L. L., Yazdanparast, H., Scheffold, A., Colomer, D., Stilgenbauer, S., Lichter, P., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16316 · Cited by 15
Kaloyannidis, P., Ayyad, A., Bahaliwah, Z., Blowi, B., Alanazi, W. A., Shamması, Z. A., Elsoudi, H., Ibrahim, I., & Hashmi, H. A. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01318-6 · Cited by 15
Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells
Fraietta, J. A., Schwab, R. D., & Maus, M. V. (2016) · Seminars in Oncology · doi:10.1053/j.seminoncol.2016.02.006 · Cited by 15
Where does PD-1 blockade fit in HL therapy?
Herrera, A. F. (2018) · Hematology · doi:10.1182/asheducation-2018.1.213 · Cited by 15
Faust, A., Bäumer, N., Schlütermann, A., Becht, M., Greune, L., Geyer, C., Rüter, C., Margeta, R., Wittmann, L., Dersch, P., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202109769 · Cited by 14
Chung, C., & Lee, R. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1509 · Cited by 14
Chimeric Antigen Receptor T-Cells
Maus, M. V., & Powell, D. J. (2015) · The Cancer Journal · doi:10.1097/ppo.0000000000000155 · Cited by 14
Cerebral aspergillosis in a patient on ibrutinib therapy—A predisposition not to overlook
Faisal, M. S., Shaikh, H. G., Khattab, A., Albrethsen, M., & Fazal, S. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218788717 · Cited by 15
Baptista, M. J., Baskar, S., Gaglione, E. M., Keyvanfar, K., Ahn, I. E., Wiestner, A. U., & Sun, C. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4894 · Cited by 14
Mechanisms of Resistance to CAR T-Cells and How to Overcome Them
Legato, L., Bisio, M., Fasano, F., Savelli, C. B., Secreto, C., Dellacasa, C. M., Botto, B., Busca, A., Cerrano, M., Freilone, R., et al. (2025) · Methods and Protocols · doi:10.3390/mps8050108 · Cited by 14
Du, Y., Lei, L., Ding, H., Chen, Y., Pathak, S., Hicks, J., Tran, P. T., Wu, M., Chang, B. Y., Wirtz, U., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.893899 · Cited by 13
Self-citationMaffei, R., Colaci, E., Fiorcari, S., Martinelli, S., Potenza, L., Luppi, M., & Marasca, R. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.09.003 · Cited by 13
Lee‐Vergés, E., Hanna, B. S., Yazdanparast, H., Rodríguez, V., Rodríguez, M. L., Giró, A., Vidal‐Crespo, A., Rosich, L., Amador, V., Aymerich, M., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.32010 · Cited by 13
The Role of Novel Agents in Treating CLL-Associated Autoimmune Hemolytic Anemia
Noto, A., Cassin, R., Mattiello, V., & Reda, G. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102064 · Cited by 13
Ibrutinib in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Systematic Review
Nepal, G., Khurana, M., Herrera-Bucheli, D., Bhandari, S., Joshi, U., Bhagat, R., Rehrig, J. H., Pudasainee, P., Shing, Y. K., Ortíz, J. F., et al. (2022) · Neurology International · doi:10.3390/neurolint14010009 · Cited by 13
CD38 as a multifaceted immunotherapeutic target in CLL
Paulus, A., Malavasi, F., & Chanan-Khan, A. A. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2090551 · Cited by 14
Ni, Y., Gao, L., Lu, Y., Ye, S., Zhou, L., Qian, W., Liang, A., & Li, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.982346 · Cited by 13
Next-generation immunotherapies for lymphoma: one foot in the future
Manson, G., & Houot, R. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy032 · Cited by 13
Discovery of a New STAT3 Inhibitor Acting on the Linker Domain
Koseki, T., Suehiro, N., Masuda, Y., Miyoshi, N., Muraoka, D., Ogo, N., & Asai, A. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b18-00992 · Cited by 13
Badar, T., Astle, J. M., Kakar, I., Zellner, K., Hari, P., & Hamadani, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16738 · Cited by 13
Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia
Far, P. M., Rullo, J., Farmer, J. P., & Urton, T. E. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2020.1841802 · Cited by 13
BTK Inhibitors in Haematology: Beyond B Cell Malignancies
Leitinger, E., & Kaplan, Z. (2022) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2022.06.009 · Cited by 12
Accelerating CAR-T Cell Therapies with Small-Molecule Inhibitors
Mestermann, K., Garitano-Trojaola, A., & Hudecek, M. (2024) · BioDrugs · doi:10.1007/s40259-024-00688-9 · Cited by 13
Hsu, L., Rosenbaum, J. T., Verner, E. J., Jones, W. B., Hill, C. M., Janc, J. W., Buggy, J. J., Pawar, R. D., Ghosh, P., Li, D., et al. (2024) · npj Drug Discovery. · doi:10.1038/s44386-024-00002-1 · Cited by 12
Self-citationGodwin, C. D., Bates, O. M., Garling, E. E., Beddoe, M. E., Laszlo, G. S., & Walter, R. B. (2020) · British Journal of Haematology · doi:10.1111/bjh.16406 · Cited by 12
Effect of Ibrutinib on the IFN Response of Chronic Lymphocytic Leukemia Cells
Xia, M., Luo, T. Y., Shi, Y., Wang, G., Tsui, H., Harari, D., & Spaner, D. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2000478 · Cited by 12
Banerjee, R. K., Fakhri, B., & Shah, N. D. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1924370 · Cited by 12
Chen, B., Zhou, D., Wei, H., Marmor, Y., Zhou, L., Cheung, J. P., Sarvaria, N., Lai, R., Sharma, S., Vishwanathan, K., et al. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15278 · Cited by 12
Thompson, P. A., Stingo, F. C., Keating, M. J., Wierda, W. G., O'Brien, S. M., Estrov, Z. E., Ledesma, C., Rezvani, K., Qazilbash, M. H., Shah, N. D., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14596 · Cited by 12
Simonowski, A., Wilhelm, T., Habib, P., Zorn, C. N., & Huber, M. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2019.118622 · Cited by 12
Duarte‐Sanmiguel, S., Shukla, V. C., Benner, B. N., Moore, J. T., Lemmerman, L. R., Lawrence, W. R., Panic, A., Wang, S., Idzkowski, N., Guio-Vega, G. P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57941-8 · Cited by 12
Moschos, S. J., Eroglu, Z., Khushalani, N. I., Kendra, K. L., Ansstas, G., In, G. K., Wang, P., Liu, G., Collichio, F. A., Googe, P. B., et al. (2021) · Melanoma Research · doi:10.1097/cmr.0000000000000726 · Cited by 12
Schliffke, S., Sivina, M., Kim, E., von Wenserski, L., Thiele, B., Akyüz, N., Falker‐Gieske, C., Statovci, D., Oberle, A., Thenhausen, T., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1417720 · Cited by 12
Primo, D., Scarfò, L., Xochelli, A., Mattsson, M., Ranghetti, P., Espinosa, A. B., Robles, A., Gorrochategui, J., Martínez‐López, J., de la Serna, J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25419 · Cited by 12
Gargiulo, E., Teglgaard, R. S., Faitová, T., & Niemann, C. U. (2023) · Acta Haematologica · doi:10.1159/000533234 · Cited by 13
Martin, D. A., Telliez, J., Pleasic‐Williams, S., Zhang, Y., Tierney, B., Blatnik, M., Gale, J. D., Banfield, C., Zhou, Y., Lejeune, A., et al. (2023) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.2347 · Cited by 11
Moraru, R., Valle‐Argos, B., Minton, A. R., Buermann, L. E., Pan, S., Wales, T. E., Joseph, R. E., Andreotti, A. H., Strefford, J. C., Packham, G., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01927 · Cited by 12
Dreger, P., & Montserrat, E. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0242-1 · Cited by 11
Ibrutinib Is Effective in the Treatment of Autoimmune Haemolytic Anaemia in Mantle Cell Lymphoma
Galinier, A., Delwail, V., & Puyade, M. (2017) · Case Reports in Oncology · doi:10.1159/000456002 · Cited by 11
Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma
Csizmar, C. M., & Ansell, S. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073302 · Cited by 13
Watanabe, T. (2021) · Cancers · doi:10.3390/cancers14010141 · Cited by 11
Graft-versus-host disease: Therapeutic prospects of improving the long-term post-transplant outcomes
Kurya, A. U., Aliyu, U., Ibrahim, A. T., Usman, A. G., Yusuf, M., Gupta, S., Ali, A. A., Gulfishan, M., Singh, S. K., Hussain, I., et al. (2022) · Transplantation Reports · doi:10.1016/j.tpr.2022.100107 · Cited by 11
Prawiro, C., Bunney, T. D., Kampyli, C., Yaguchi, H., Katan, M., & Bangham, C. R. M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166601 · Cited by 11
Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
van Bruggen, J. A. C., Martens, A. W. J., Tonino, S. H., & Kater, A. P. (2020) · Cancers · doi:10.3390/cancers12123837 · Cited by 11
Mikulková, Z., Manukyan, G. P., Turcsányi, P., Kudělka, M., Urbanová, R., Savara, J., Ochodková, E., Brychtová, Y., Molinský, J., Šimkovič, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-020-79121-4 · Cited by 11
Paccoud, O., Bougnoux, M., Desnos‐Ollivier, M., Varet, B. R., Lortholary, O., & Lanternier, F. (2021) · Journal of Fungi · doi:10.3390/jof7030212 · Cited by 11
Vaccine Strategies for the Treatment of Lymphoma: Preclinical Progress and Clinical Trial Update
Marron, T. U., Ronner, L., Martin, P., Flowers, C. R., & Brody, J. (2016) · Immunotherapy · doi:10.2217/imt-2016-0080 · Cited by 11
Manukyan, G. P., Turcsányi, P., Mikulková, Z., Gabčová, G., Urbanová, R., Gajdoš, P., Kraiczová, V. Š., Zehnalová, Š., Papajík, T., & Kriegová, E. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.08.006 · Cited by 11
Huber, H., Edenhofer, S., Estenfelder, S., & Stilgenbauer, S. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s102646 · Cited by 10
Miklos, D. B., Riedell, P. A., Bokun, A., Chávez, J. C., & Schuster, S. J. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01133-9 · Cited by 11
Chalmers, S. A., Garcia, S. J., Webb, D. S. A., Herlitz, L., Fine, J. S., Klein, E. S., Ramanujam, M., & Putterman, C. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108640 · Cited by 10
Immune thrombocytopenia: options and new perspectives
Caserta, S., Zaccuri, A. M., Innao, V., Musolino, C., & Allegra, A. (2021) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001058 · Cited by 10
Ibrutinib directly reduces CD8+T cell exhaustion independent of BTK
Li, L., Zhao, M., Kiernan, C. H., Eiro, M. D. C., van Meurs, M., Brouwers-Haspels, I., Wilmsen, M. E. P., Grashof, D. G. B., van de Werken, H. J. G., Hendriks, R. W., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1201415 · Cited by 10
Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
Zhao, M., Li, L., Kiernan, C. H., Eiro, M. D. C., Dammeijer, F. F., van Meurs, M., Brouwers-Haspels, I., Wilmsen, M. E. P., Grashof, D. G. B., van de Werken, H. J. G., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42871-y · Cited by 10
Vitale, C., Griggio, V., Perutelli, F., & Coscia, M. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000988 · Cited by 10
Barragan, A. M., Ghaby, K., Pond, M. P., & Roux, B. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00023 · Cited by 10
Othman, T. A., Frankel, P. H., Allen, P. B., Popplewell, L. L., Shouse, G., Siddiqi, T., Danilov, A. V., Ruel, N. H., Daniels, S., Peters, L., et al. (2024) · Haematologica · doi:10.3324/haematol.2024.285185 · Cited by 10
Metadata
- Authors
- Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., Stefanovski, M. R., Chappell, D. L., Frissora, F. W., Smith, L. L., Smucker, K. A., Flynn, J. M., Jones, J. A., Andritsos, L. A., Maddocks, K., Lehman, A. M., Furman, R., Sharman, J., Mishra, A., Caligiuri, M. A., Satoskar, A. R., Buggy, J. J., Muthusamy, N., Johnson, A. J., & Byrd, J. C.
- Affiliations
- Department of Internal Medicine, Division of Hematology,
- The Ohio State University (US)
- Pharmacyclics (United States) (US)
- Weill Cornell Medicine (US)
- Willamette Valley Cancer Institute and Research Center (US)
- Department of Pathology, and
- ORCID
- Beckwith, Kyle A.
- Natarajan, Gayathri
- Woyach, Jennifer A.
- Jaglowski, Samantha
- Chang, Betty Y.
- Chappell, Danielle L.
- Smith, Lisa L.
- Flynn, Joseph M.
- Jones, Jeffrey A.
- Andritsos, Leslie A.
- Maddocks, Kami
- Furman, Richard
- Sharman, Jeff
- Mishra, Anjali
- Caligiuri, Michael A.
- Satoskar, Abhay R.
- Muthusamy, Natarajan
- Johnson, Amy J.
- Byrd, John C.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2013-10-10
- Volume
- 122
- Issue
- 15
- Pages
- 2539-2549
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- PMC
- PMC3795457
- OpenAlex
- W2089103836
- Cited by
- 810
- References
- 49
- Citations by year
- 2026: 30 · 2025: 43 · 2024: 55 · 2023: 51 · 2022: 70 · 2021: 98 · 2020: 68 · 2019: 71 · 2018: 71 · 2017: 70 · 2016: 65 · 2015: 67 · 2014: 43 · 2013: 5
- FWCI
- 29.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Blood (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (4p01ca081534-16)
- National Cancer Institute (P01CA095426, P50CA140158, T32CA009338, 5 T32 CA009338-33-03, P30CA016058, K12CA133250, P01-CA-081534)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- ibrutinib, irreversible kinase inhibitors, Bruton's tyrosine kinase, T cell signaling, Th1 response, Th2 immune response, chronic lymphocytic leukemia, Leishmania major, Listeria monocytogenes, immunomodulation
- MeSH terms
- Adenine, Animals, Disease Models, Animal, Enzyme Inhibitors, Humans, Leukemia, Listeriosis, Lymphocyte Activation, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Leishmaniasis, Cutaneous, CD8-Positive T-Lymphocytes, Th1 Cells, Th2 Cells, Jurkat Cells, Mice, Primary Cell Culture
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
